Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.'
Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.'
Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph).
About High Tech Medical Pty Ltd.Founded in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence.
About ELIXIR MD, Inc.Based in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide. www.ELIXIRMD.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 hours ago
- The Star
Rugby-Rugby Australia chief certain Lions will return in 2037, Giteau Law scrapped
FILE PHOTO: Rugby Union - Australia v British & Irish Lions - Third Test - Accor Stadium, Sydney, Australia - August 2, 2025 Australia celebrate their win over the Lions Dean Lewins/AAP Image via REUTERS/File Photo SYDNEY (Reuters) -Rugby Australia chief Phil Waugh was disappointed the Wallabies lost the test series against the British & Irish Lions but believes the tour was a huge success and talk that the tourists might not return in 2037 was well wide of the mark. Some media pundits had suggested after the Lions comfortably won the first test in Brisbane that Australian rugby was so weak the country no longer deserved its place on the touring rotation along with New Zealand and South Africa. Waugh thought the competitiveness of the Wallabies in the second test in Melbourne, where they came within seconds of victory, and the third in Sydney, where they won 22-12, had firmly quashed any speculation about the Lions not returning. "Australia is a really important home for the Lions tour every 12 years," the RA chief executive told reporters at the conclusion of the series. "On the field, I think the accumulative points, they got one point better than us and one try better than us, and it was a really fierce test battle. "So I think any of that speculation, it was shut down by a number of people, including their CEO, who spoke at various events committing to return to Australia." Waugh thought the second test, which attracted a crowd of 90,307 to the Melbourne Cricket Ground, was one of the best internationals he had seen in a while and said he had been impressed with the Wallabies throughout the series. "I think it's been an overwhelmingly successful tour, albeit would have been nice to win the ... trophy, but that wasn't to happen," he added. "I think that the progress that's continued through the group, and I think the cultural growth of the group, has been really, really pleasing." Around 450,000 fans attended the nine matches and Waugh said the tour had exceeded expectations on financial returns for both RA and the Lions. REDUCE DEBT Exactly what the returns were was still being calculated, he said, but Australia's proceeds would go to reducing the A$80 million ($51.78 million) credit facility RA took out in 2023, which cost more than A$9 million to service last year. "It certainly exceeded expectations," Waugh said. "I've always said that it's a really good opportunity for us to reset the balance sheet. "We've got the debt facility, and ideally we pay that down as quickly as possible, given the cost to carry it ... then we'll lean into the next broadcast cycle to get to a financially sustainable model." The Wallabies got great returns in the series from Will Skelton, the wrecking ball of a lock who was recalled from his French club to take on the Lions. Tighthead prop Taniela Tupou, who played a key role in the third test victory, will also be moving to a French club this year, which would once have made him ineligible to play for the Wallabies. That blanket ban was eased ahead of the 2015 World Cup under the 'Giteau Law', which allowed the Wallabies coach to select three overseas-based players under certain criteria. RA's Director of High Performance Peter Horne confirmed that all restrictions on test selection had been scrapped when Joe Schmidt took over as Wallabies coach last year. "Joe's got no impediment to select whoever he wants. That's always been the case. The Giteau Law's kind of redundant," he said. "But we've also made a choice that we select domestically if the players are of equal calibre, it's important that we invest in our premier competition in Australia." ($1 = 1.5451 Australian dollars) (Reporting by Nick Mulvenney, editing by Ken Ferris)
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Nuna Selected by White House and CMS to Join Landmark Health Tech Ecosystem Initiative
SAN FRANCISCO, Aug. 4, 2025 /PRNewswire/ — Nuna announced its selection to join the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem, a landmark public-private initiative designed to transform healthcare for Americans. The initiative was unveiled at a White House event on Wednesday by President Donald Trump, CMS Administrator Dr. Mehmet Oz, HHS Secretary Robert F. Kennedy Jr., and Amy Gleason, Acting Administrator of DOGE. The event was attended by a select group of healthcare leaders and innovators, including Nuna Founder and CEO, Jini Kim. As part of the ecosystem, Nuna will contribute its expertise to two cornerstone efforts: Conversational AI Assistance and Diabetes & Obesity Prevention and Management. 'We're honored to stand alongside CMS in this bold and necessary step forward in healthcare,' said Jini Kim. 'We believe health isn't just built in the hospital or clinic; it's forged in the small moments of our daily lives. That's why we created Nuna, a trusted digital companion to help people succeed on their health journey, one day at a time.' Nuna's pledge is centered on its AI-powered digital engagement platform. Nuna's app empowers patients to confidently manage their chronic conditions through a combination of 24/7 conversational support, motivating gamification, and direct linkage to their clinical care team. This integrated approach drives powerful results: 72% of users with uncontrolled hypertension achieve control and 73% remain active after six months. By connecting daily patient behavior to the clinical team, Nuna bridges a critical gap in today's healthcare landscape by enabling timely, proactive intervention by care teams for their patients. 'Nuna has been a game changer for patients struggling with chronic conditions,' said David Ansell, MD, of Rush University System for Health and a Nuna development partner. 'It extends care from the clinic to the home and its AI enhanced education engages patients in behavioral change that persists over time. The result being better blood pressure control and improved health behaviors. Early results suggest it can crack the code on chronic disease self-management by engaging people to attend to their health when they are in their homes. This type of tech innovation has great potential to transform primary and preventive care across the US.' About Nuna Nuna is a digital health company dedicated to transforming chronic care by empowering patients and their clinicians. Its AI-driven platform provides personalized, continuous support to help people manage their health and chronic conditions in the moments that matter most. Nuna partners with health systems and health plans to improve patient outcomes, enhance care team efficiency, and reduce the overall cost of care. For more information about Nuna's participation in the CMS Digital Health Ecosystem, visit or contact press@
New Straits Times
16 hours ago
- New Straits Times
Japan's Mitsubishi Q1 profit down 43pct, beats expectations
TOKYO: Japanese trading house Mitsubishi on Monday posted a net profit of 203.1 billion yen (US$1.4 billion) in the three months to June 30, down 43 per cent from a year ago but beating analysts' forecasts. An LSEG poll of analysts had expected the company to post 180.3 billion yen in the first-quarter net profit. In the same period of last year, Mitsubishi saw a net profit of 354.4 billion yen. This year, the profit was mainly down due to the absence of gains from asset sales and weaker prices in the Australian steelmaking coal business, the company said. Mitsubishi left its forecast for the fiscal year ending next March unchanged at 700 billion yen. Billionaire investor Warren Buffett's Berkshire Hathaway has taken minority stakes in Japan's top five trading houses, including Mitsubishi.
